Please login to the form below

Not currently logged in
Email:
Password:

Vernalis

This page shows the latest Vernalis news and features for those working in and with pharma, biotech and healthcare.

Vernalis accepts £33m takeover offer from Ligand Pharma

Vernalis accepts £33m takeover offer from Ligand Pharma

Vernalis accepts £33m takeover offer from Ligand Pharma. After mulling over several takeover offers, UK biotech Vernalis has been won over by an overture from California’s Ligand Pharma that values ... If Ligand’s offer is approved by Vernalis

Latest news

  • FDA knocks-back second Vernalis cough and cold treatment FDA knocks-back second Vernalis cough and cold treatment

    FDA knocks-back second Vernalis cough and cold treatment. US regulator delivers another complete response letter to the UK firm. ... Vernalis’hopes of bringing either of its cough-cold drugs CCP-07 and CCP-08 to the US market in time for the 2017-2018

  • Juno cleared to restart CAR-T trial after deaths Juno cleared to restart CAR-T trial after deaths

    Vipadenant was originally developed as a Parkinson's disease candidate by UK company Vernalis and licensed to Biogen, but its development was held back by safety concerns and Biogen eventually abandoned

  • Vernalis Therapeutics appoints president and COO Vernalis Therapeutics appoints president and COO

    UK-based Vernalis Therapeutics has appointed Sandford Sommer as its new president and chief operating officer. ... Sommer said: “ I am excited to be joining Vernalis at such an important time. “

  • Merck & Co drops Parkinson's prospect preladenant Merck & Co drops Parkinson's prospect preladenant

    2011. Meanwhile, Lundbeck was also working in this area with its Lu AA47070, but discontinued this project a couple of years ago, while Vernalis and Biogen Idec dropped their own candidate

  • Pharma deals for February 2012 Pharma deals for February 2012

    The CEO explained that the deal “ is fundamental in transitioning Vernalis into a diversified and self-sustaining pharmaceutical company.”. ... 124. Tris / Vernalis (a). License, development and commercialisation. Development of US Rx cough products

More from news
Approximately 3 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Corporate acquisition. 245††. Vernalis/ Not disclosed. Adenosine receptor antagonist programme, including the lead drug candidate, V81444.

  • Pharma deals in February 2015 Pharma deals in February 2015

    Keeping the romance under wraps. It was announced in February that Vernalis has licensed its proprietary adenosine receptor antagonist programme, including the phase 1/2 lead compound V81444, for use in

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...
Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...

Infographics